Swmg LLC Takes $1.53 Million Position in Novo Nordisk A/S $NVO

Key Points

• Swmg LLC acquired a new stake in Novo Nordisk A/S worth approximately $1.53 million during the second quarter, purchasing 22,130 shares of the company.
• Novo Nordisk reported an earnings per share (EPS) of $0.97 for the last quarter, exceeding analysts' expectations of $0.93, and had a return on equity of 78.64%.
• The company declared a semi-annual dividend of $0.4119 per share, leading to a dividend yield of 240.0%, although it has a payout ratio of 22.53%.

Swmg LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 22,130 shares of the company's stock, valued at approximately $1,527,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. acquired a new stake in Novo Nordisk A/S during the first quarter worth about $27,000. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth about $30,000. Disciplina Capital Management LLC increased its stake in Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after acquiring an additional 297 shares during the last quarter. Finally, Spirit of America Management Corp NY acquired a new stake in Novo Nordisk A/S during the first quarter worth about $35,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $54.41 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $118.26. The business has a 50-day moving average of $56.24 and a 200-day moving average of $62.72. The company has a market capitalization of $242.93 billion, a price-to-earnings ratio of 14.95, a PEG ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's payout ratio is 22.53%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NVO shares. Hsbc Global Res upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 1st. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Finally, UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.